Prior to performing KRAS mutation detection on any plasma derived DNA, the corresponding matched FFPE tissue was screened using the therascreen KRAS RGQ PCR kit to identify patients with mutation positive tumours (n = 10/20; data not shown). This evidence concerns the gene KRAS and neoplasm.